EARLIER DETECTION.
BETTER OUTCOMES.

A blood test designed to improve Lyme disease detection across all stages of the disease.

Commercial launch anticipated in 2027.

Our mission is to transform the detection of Lyme disease through science-driven innovation. We are committed to developing accurate, accessible, and early-stage diagnostics that empower patients, inform clinicians, and improve outcomes.

We are Aces Diagnostics

Aces Diagnostics is dedicated to transforming Lyme disease diagnosis through innovation, science, and patient-centered solutions.

Our team brings together expertise in Lyme disease research, diagnostics, artificial intelligence, regulatory strategy, and commercialization. Through LYMESEEK™, we aim to provide physicians with a more accurate tool for detecting Lyme disease earlier, enabling faster treatment decisions and improved patient outcomes.

CREATORS OF

Learn About LYMESEEK™

The Problem

Current tests miss ~70%
of early Lyme infection

Current Lyme disease tests frequently miss infections during the earliest stages of disease, delaying treatment and increasing the risk of long-term health complications.

Copy of AcesDiagnostic May 21 2026 Version (1).png

The Solution

Earlier Detection.
Better Outcomes.

>90% Accuracy

Validated on 1,000+ clinical samples across U.S. and E.U. populations.

Single Test

Only one blood draw is required

Lab Ready

Runs on existing clinical laboratory equipment

LYMESEEK™ is a single blood test that combines proprietary biomarkers with machine learning to enable earlier, more accurate Lyme disease detection when treatment is most effective.

Learn About LYMESEEK™

The Impact

PATIENTS
Earlier Answers

Early diagnosis may improve outcomes and reduce the risk of long-term complications.

PHYSICIANS
Greater Diagnostic Confidence

Accurate, objective results support earlier treatment decisions.

PAYERS
Reduced Healthcare Costs

Fewer unnecessary tests, specialist referrals, and delayed diagnoses.

Economic Impact

Independent analysis indicates significant healthcare cost savings through earlier and more accurate Lyme disease diagnosis.

Boston Strategic Partners projects LYMESEEK™ could reduce Lyme-related healthcare costs by $3.2 Billion annually through earlier diagnosis and intervention.

Our Progress Toward Commercialization

Aces Diagnostics has completed key development and validation milestones and is advancing toward pivotal clinical trials, regulatory clearance, and commercial launch.

Screenshot_30-9-2024_15329_lightroom.adobe_edited.jpg

Olivia Walker

Editor in Chief

Dan Mitchell

Assistant Manager

Noah Patterson

Programming Editor

Tess Anderson

Art Director

Tess Anderson

Art Director

DISCOVERY PHASE

2014-2023

Identified propriety biomarkers and AI-driven diagnostic approach.

TEST DEVELOPMENT

2024

Assay design and algorithm development

VERIFICATION & VALIDATION

2025-2026

Validated on 1,000+ clinical samples across U.S. and E.E. populations.

CLINICAL TRIALS & REGULATORY SUBMISSION

2026-2027

Preparing for pivotal FDA clinical trials and regulatory review.

COMMERCIAL LAUNCH

2027

Clinical laboratory partnerships and market introduction.

Partner With Us

We welcome conversations with investors, clinical laboratory partners, healthcare organizations, and industry leaders who share our vision of improving Lyme disease diagnosis.